Swiss biotech sidesteps Covid with record investment
Swiss biotechnology companies invested a record CHF2.6 billion ($2.7 billion) into research last year despite most concentrating their efforts away from the coronavirus pandemic.
This content was published on
1 minute
swissinfo.ch/mga
Português
pt
Biotecnologia suíça consegue investimento recorde apesar da Covid
Research was instead focused on areas such as immuno-oncology, neurology and emerging areas such as cell-based therapies, according to the annual Swiss Biotech Report from consultancy group EY Switzerland.
The industry achieved sales of CHF6.7 billion in 2021, up from CHF4.9 billion the year before. But the global pandemic had a surprisingly detrimental effect on the health of the Swiss biotech industry.
Funding fell away slightly to CHF3.3 billion as investors concentrated on fighting the Covid-19 pandemic. “As a result, some companies have not received the financing they may need to survive,” said Frederik Schmachtenberg, life sciences expert at EY Switzerland, on Tuesday.
Some three to five percent of small biotech companies fell into severe financial difficulties or had to shut down, said Michael Altorfer, CEO of the Swiss Biotech Association, on Tuesday.
“Over the past year, I’ve been far more concerned about the potential financial problems of individual companies,” he said.
But the report authors hope that funding will return to other research areas as the global pandemic looks to be coming under control this year.
Switzerland has some 323 biotech companies, employing around 17,855 people, which is a 9.5% increase in employees from 2020.
This content was published on
Viola Amherd has expressed her “deep shock” at the assassination attempt on Slovakian Prime Minister Robert Fico on Wednesday.
This content was published on
A man injured half a dozen people with knives, two of them seriously, before being arrested on Wednesday in northern Switzerland.
Switzerland to introduce flight passenger database
This content was published on
Switzerland plans to introduce a flight passenger database to collect and process personal data in a bid to combat terrorism and serious crime.
Government plans to invest over CHF16bn in Swiss rail network
This content was published on
The federal government intends to invest CHF16.4 billion ($18.1 billion) in railway infrastructure between 2025 and 2028, CHF2 billion more than for the current period.
Swiss to vote on pension reform and biodiversity in September
This content was published on
Swiss citizens will vote on occupational pension schemes and a biodiversity initiative on September 22, the Federal Council announced on Wednesday.
Ukraine peace talks: 50 countries have confirmed participation
This content was published on
To date, 50 countries out 160 invited delegations have confirmed they will attend the Ukraine peace conference, held in central Switzerland in mid-June, according to Swiss public radio, RTS.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Looming bacterial pandemic triggers debate over how to pay for new antibiotics
This content was published on
Few big pharmaceutical companies have a stake in new antibiotics research. Financial incentives could help, but they are controversial.
Switzerland approves its first protein-based Covid vaccine
This content was published on
The Swiss medical regulator has approved the Nuvaxovid vaccine for adults making it the fourth Covid-19 vaccine authorised in the country.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.